Hudson Bay Capital Management
OCUL icon

Hudson Bay Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Hudson Bay Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,540
Closed -$106K – 1586
2026
Q1 		$106K Buy
+12,540
New +$120K ﹤0.01% 1176
2025
Q4 		– Sell
-50,039
Closed -$585K – 1442
2025
Q3 		$585K Sell
50,039
-4,051
-7% -$48.4K ﹤0.01% 904
2025
Q2 		$502K Buy
+54,090
New +$423K ﹤0.01% 1084

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hudson Bay Capital Management's OCUL Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 12,540 shares — an estimated $106K sold.

Hudson Bay Capital Management first reported a position in OCUL in Q2 2025 and held it in 3 quarters. The position peaked at $585K in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 12,540 Ocular Therapeutix shares in Q2 2026, an estimated $106K.
  • Hudson Bay Capital Management first reported a position in Ocular Therapeutix in Q2 2025 and held it in 3 quarters.
  • Hudson Bay Capital Management's Ocular Therapeutix position peaked at $585K in Q3 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.